TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29378651

Group type: EXPERIMENTAL
Intervention: ABvac40
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26995376

Group type: EXPERIMENTAL
Intervention: Exenatide once‐weekly 2 mg
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14000
Study: 25125339

Group type: EXPERIMENTAL
Intervention: Exercise and dietary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 22545567

Group type: EXPERIMENTAL
Intervention: PTSD, dissociative disorders, rape by an intimate partner, duration of CSA, number of perpetrators of CSA
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard behavioral prevention interventions
Number of subjects: 57
Study: 20649832

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 150

Group type: COMPARATOR
Intervention: Silver sulphadiazine (SSD)
Number of subjects: 150
Study: 17711927

Group type: EXPERIMENTAL
Intervention: BW-ADAPTED-T4 (1.6 microg/kg bw T4)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: BW-ADAPTED-T3T4 (combination of T3 and T4 at a ratio of 1:10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: EMPIRICAL-T4 (1 +/- 0.05 microg/kg bw)
Number of subjects: 29
Study: 15846250

Group type: EXPERIMENTAL
Intervention: Elective stent implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IVUS findings
Number of subjects: 40
Study: 12143089

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo appliance
Number of subjects: 21
Study: 10546333

Group type: EXPERIMENTAL
Intervention: Oral exposure to one of the shapes for 90 seconds prior to visual stimuli testing (Experiment 1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Less side bias group (Experiment 2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Replication of Meltzoff and Borton's experiment (Experiment 3)
Number of subjects: 96
Study: 7481021

Group type: EXPERIMENTAL
Intervention: Propofol (sleep doses and N2O)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol (10 mg/kg/h intravenous perfusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thiopental and N2O
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dehydrobenzylperidol (90 micrograms/kg) i.m. followed by sleep doses of propofol
Number of subjects: 80
Study: 1980654

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7006617

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30553512

Group type: EXPERIMENTAL
Intervention: Body weight variability (BWV)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Weight gain quartile
Number of subjects: 10251
Study: 28616847

Group type: EXPERIMENTAL
Intervention: IVR calls (5 calls over 3 months)
Number of subjects: 878
Study: 25621791

Group type: EXPERIMENTAL
Intervention: Clonidine (α2‐adrenergic agonist)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Scopolamine (muscarinic antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24295013

Group type: EXPERIMENTAL
Intervention: Concave bevel (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Straight bevel (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 21094025

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (n=39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control condition (n=38)
Number of subjects: 77
Study: 19208714

Group type: EXPERIMENTAL
Intervention: Nurses performing endoscopy
Number of subjects: 1888

Group type: COMPARATOR
Intervention: Doctors performing endoscopy
Number of subjects: 1888
Study: 17558641

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: normal control group
Number of subjects: 40
Study: 15190052

Group type: EXPERIMENTAL
Intervention: Combination of vitamins and minerals (200 mg Mg and 30 mg Zn + 200 mg vitamin C and 150 mg vitamin E)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vitamin C and E (200 mg vitamin C and 150 mg vitamin E)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Mg and Zn (200 mg Mg and 30 mg Zn)
Number of subjects: 69
Study: 12200215

Group type: EXPERIMENTAL
Intervention: Divalproex (b.i.d./t.i.d.)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Extended-release divalproex (qd)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 43
Study: 9708227

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide for 12 hours, then stopped
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide for 36 hours
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide for 60 hours
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 106
Study: 7831492

Group type: EXPERIMENTAL
Intervention: Daily administration of a stroking procedure
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Placement on a multisensory hammock during sleep periods
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of stroking procedure and multisensory hammock
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (natural caregiving)
Number of subjects: 49
Study: 2477338

Group type: EXPERIMENTAL
Intervention: Potassium hydrochloride 1 g twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Potassium hydrochloride 1 g and magnesium hydroxide 500 mg twice daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 11
Study: 334435

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metolazone, 5 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29366340

Group type: EXPERIMENTAL
Intervention: Strength exercise (squat training, 3 times a week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (education programme)
Number of subjects: 40
Study: 26848624

Group type: EXPERIMENTAL
Intervention: High hs-CRP levels (≥ 13.1 mg/L)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Low hs-CRP levels (< 13.1 mg/L)
Number of subjects: 132
Study: 25239582

Group type: EXPERIMENTAL
Intervention: Stairclimbing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cycle ergometer test
Number of subjects: 10
Study: 22925817

Group type: EXPERIMENTAL
Intervention: 600 μg of rectal misoprostol
Number of subjects: 218

Group type: COMPARATOR
Intervention: 20 intravenous units of oxytocin
Number of subjects: 218
Study: 20371660

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d for 8 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Niaspan (2000 mg/d for 16 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 27
Study: 17439513

Group type: EXPERIMENTAL
Intervention: Phloroglucinol/trimethylphloroglucinol (62.2 mg P + 80 mg TMP) two pills three times daily for 7 days
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Phloroglucinol/trimethylphloroglucinol
Number of subjects: 307
Study: 16270644

Group type: EXPERIMENTAL
Intervention: Certoparin (3000 anti-Xa IU, subcutaneously, once-daily)
Number of subjects: 6124

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU, subcutaneously, three-times daily)
Number of subjects: 6124

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 6124

Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 6124
Study: 12065973

Group type: EXPERIMENTAL
Intervention: Supplemental pedicle screw fixation (instrumented)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No pedicle screw instrumentation (noninstrumented)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups (instrumented and noninstrumented)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Noninstrumented fusion
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Instrumented fusion
Number of subjects: 129
Study: 10384248

Group type: EXPERIMENTAL
Intervention: Stress-management training (education, relaxation, D'Zurilla problem-solving training)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Stress-management training
Number of subjects: 21
Study: 7610658

Group type: EXPERIMENTAL
Intervention: Randomized group A (general population)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Group B (symptom-free 'healthy' subgroup)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Group D (persons with allergic rhinitis)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Group C (asthmatic persons)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall sensitization in asthmatic group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall sensitization in randomized group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Increased serum levels of total IgE or specific IgE
Number of subjects: 600
Study: 2203273

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 50
Study: 215095

Group type: EXPERIMENTAL
Intervention: Procyclidine hydrochloride
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31215727

Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: dulaglutide
Number of subjects: 0
Study: 27243916

Group type: EXPERIMENTAL
Intervention: Grouped exercises (GE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Separated exercises (SE)
Number of subjects: 20
Study: 26214438

Group type: COMPARATOR
Intervention: BIS monitoring group (A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 23563560

Group type: EXPERIMENTAL
Intervention: Chicken collagen hydrolysate (CCH) 2.9 g/d
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 21147417

Group type: EXPERIMENTAL
Intervention: TrP pressure release
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 20
Study: 18317438

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir (300/100 mg)
Number of subjects: 9
Study: 16570047

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 38
Study: 12649101

Group type: EXPERIMENTAL
Intervention: GM-CSF mouthwash 150 micro g/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10874052

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 2 g/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 34
Study: 9288186

Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 or PSM-P2 (groups 4 and 5)
Number of subjects: 7

Group type: COMPARATOR
Intervention: PSM-P1 or PSM-P2 alone (groups 1 and 2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Autologous DC (group 3)
Number of subjects: 7
Study: 7936832

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg birth weight at 12-18 h of age and a second dose 12 h later)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (i.v. saline)
Number of subjects: 40
Study: 3230235

Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat meal
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Meal containing MCT oil
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 1
Study: 29500968

Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet high in ALA (3.4 g/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control diet low in ALA (0.9 g/d)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 81
Study: 24190696

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (150 mg daily recommended dose, administered in three 50 mg doses across the day and evening)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Number of subjects: 24
Study: 23038965

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (60 mg/m2 per administration) and continuous infusion of cytarabine during the second course
Number of subjects: 145

Group type: COMPARATOR
Intervention: High-dose HAM protocol as a second induction course
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: High-dose anthracycline antibiotics
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Protocol deviations
Number of subjects: 145
Study: 21265466

Group type: EXPERIMENTAL
Intervention: Co‐Ir‐vell tablets (test formulation)
Number of subjects: 24
Study: 18541232

Group type: EXPERIMENTAL
Intervention: Phytoestrogen genistein (54 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16420786

Group type: EXPERIMENTAL
Intervention: Liver resection (LR)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Segmentary resections with Pringle maneuver
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Second 100 resections
Number of subjects: 177
Study: 12844276

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (n=23)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: tibolone (n=23)
Number of subjects: 70
Study: 10846122

Group type: EXPERIMENTAL
Intervention: Wand system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 40
Study: 8619364

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 25 micrograms/kg/day, n = 5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose IGF-I 60 micrograms/kg b.i.d., n = 5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose IGF-I 15 micrograms/kg b.i.d., n = 6
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose IGF-I
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose IGF-I
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 16
Study: 2248030

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 600 mg daily for 7 days (monotherapy in 53.2% of cases)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 600 mg daily for 7 days (in association with antibiotics in 46.8% of cases)
Number of subjects: 1186
Study: 7362419

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose prediction
Number of subjects: 0
Study: 31809992

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) enriched with extra-virgin olive oil (EVOO)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 720
Study: 30794429

Group type: EXPERIMENTAL
Intervention: Dairy snack (Greek yogurt, 198.9 g, 171 kcal, 0 g fat, 17 g protein)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nondairy snack (mini sandwich-type cookies, 37.5 g, 175 kcal, 7.5 g fat, 1.3 g protein)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dairy snack (Greek yogurt)
Number of subjects: 18
Study: 27864713

Group type: EXPERIMENTAL
Intervention: Uncovered double bare metal stent (DBS; S&G Biotech Inc.)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Uncovered single bare metal stent (SBSs; S&G Biotech Inc.)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Uncovered single bare metal stent (SBSt; Taewoong Medical)
Number of subjects: 71
Study: 25156798

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐Up (ABC) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 100
Study: 22946099

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET) - 40‐60 min cycling at ∼65%, 5 times per week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) - 4‐6 Wingate tests, 3 times per week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both ET and SIT
Number of subjects: 16
Study: 22005602

Group type: EXPERIMENTAL
Intervention: Brief sleep program (1 session)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Extended sleep program (2-3 sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 27
Study: 19225067

Group type: EXPERIMENTAL
Intervention: Chemotherapy or therapy with epidermal growth factor receptor (EGFR) inhibitors
Number of subjects: 8579

Group type: COMPARATOR
Intervention: Docetaxel therapy every 3 weeks
Number of subjects: 8579
Study: 17113676

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0-15 min before breakfast and dinner)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Regular human insulin (RHI) (30-45 min before breakfast and dinner)
Number of subjects: 890
Study: 15161783

Group type: EXPERIMENTAL
Intervention: Ragaglitazar 1 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Ragaglitazar 4 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Ragaglitazar 10 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 11309650

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC, n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open colectomy (OC, n = 24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC, n = 20)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open colectomy (OC, n = 15)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 50
Study: 9386068

Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 125

Group type: COMPARATOR
Intervention: Coronary Bypass Surgery
Number of subjects: 125
Study: 8001939

Group type: EXPERIMENTAL
Intervention: Blood samples for measurement of plasma zinc levels; Lavage of the vagina and ectocervix with sterile saline solution for measurement of cervicovaginal zinc levels.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (15 women without anamnesis of vulvovaginal candidiasis).
Number of subjects: 21
Study: 3046811

Group type: EXPERIMENTAL
Intervention: Theophylline (5.5 mg/kg administered intravenously)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pancreatic enzymes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28300339

Group type: EXPERIMENTAL
Intervention: Structured feedback after the interview
Number of subjects: 38

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 38
Study: 26911396

Group type: EXPERIMENTAL
Intervention: 0.5 mg/0.05 ml IVI of bevacizumab (IVB group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.25 mg/0.05 ml IVI of ranibizumab (IVR group)
Number of subjects: 60
Study: 25715386

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 20
Study: 23075915

Group type: COMPARATOR
Intervention: Etravirine alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Boceprevir alone
Number of subjects: 20
Study: 21393589

Group type: EXPERIMENTAL
Intervention: Radial arterial access
Number of subjects: 51

Group type: COMPARATOR
Intervention: Femoral arterial access
Number of subjects: 51
Study: 18489398

Group type: EXPERIMENTAL
Intervention: DK crush
Number of subjects: 311

Group type: COMPARATOR
Intervention: Classical crush
Number of subjects: 311
Study: 16282244

Group type: EXPERIMENTAL
Intervention: rhAngiostatin at 15 mg or 60 mg twice daily in combination with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhAngiostatin at 15 mg or 60 mg twice daily
Number of subjects: 24
Study: 12691140

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Melphalan and prednisone
Number of subjects: 52
Study: 10902528

Group type: EXPERIMENTAL
Intervention: Virtual Learning Environment (VLE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Lecture Hall
Number of subjects: 0
Study: 8714363

Group type: EXPERIMENTAL
Intervention: Cordaflex 20 mg retard film coated tablets
Number of subjects: 31

Group type: COMPARATOR
Intervention: Adalat 20 mg retard film coated tablets
Number of subjects: 31
Study: 1562025

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment for a mean period of 4 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 22
Study: 6694867

Group type: EXPERIMENTAL
Intervention: Peer counseling
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nurse counseling
Number of subjects: 57
Study: 30296402

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (watching a nature documentary)
Number of subjects: 25
Study: 30012526

Group type: EXPERIMENTAL
Intervention: Immunotherapy plus stereotactic body radiation therapy (50 Gy/4 fractions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immunotherapy plus 45 Gy/15 fractions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Twice-daily chemoimmunoradiotherapy (45 Gy in twice-daily fractions)
Number of subjects: 60
Study: 26521866

Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 208

Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 208